WuXi Biologics has begun construction of a $20 million state-of-the-art integrated biologics conjugate R&D/CDMO center in Wuxi city, China. The company said the 6,000 square meter facility, which will become operational in 2019, will provide a full suite of services stretching from concept to commercialization for antibody-drug conjugates (ADCs) and other protein conjugates. In the last three months, WuXi has announced five new facilities around the globe at a total cost of $812 million.
Source: China Biotoday
